Marginal effects from results of segmented regression analysis
| Group | Drug price reduction in December 2012 (compared to March 2012) | New guidelines in October 2013 (compared to January 2013) | Both policies in December 2013 (compared to March 2012) | |
|---|---|---|---|---|
| Daily drug utilisation | All | +0.0153 | −0.0307* | −0.0050 |
| Health insurance | +0.0157 | −0.0306 | −0.0043 | |
| Medical aid | +0.0023 | −0.0377* | −0.0394 | |
| Average number of drugs per month | All | −0.0121* | −0.1612* | −0.1883* |
| Health insurance | −0.0119* | −0.1621* | −0.1886* | |
| Medical aid | −0.0224 | −0.1484* | −0.1972 | |
| Per cent of original drugs (%) | All | +0.0947 | +0.2197 | +0.5402 |
| Health insurance | +0.1483 | +0.1124 | +0.5267 | |
| Medical aid | −0.4887 | +1.6364 | +0.9739 | |
| Drug overutilisation (probability) | All | +0.00358 | −0.00206 | +0.00544 |
| Health insurance | +0.00350 | −0.00206 | +0.00522 | |
| Medical aid | +0.00240 | −0.02158 | −0.01912 | |
| Prohibited combination (probability) | All | +0.00768 | −0.00719 | +0.00952 |
| Health insurance | +0.00765 | −0.00704 | +0.00979 | |
| Medical aid | −0.00795 | −0.00652 | −0.04079 | |
| Antihypertensive drug costs (USD) | All | −1.5137* | −2.1272* | −4.2217* |
| Health insurance | −1.5304* | −2.1128* | −4.2312* | |
| Medical aid | −1.2514 | −2.3844 | −4.0456 | |
| Antihypertensive drug cost per prescribing day (USD) | All | −0.0442 | −0.0732* | −0.1346 |
| Health insurance | −0.0450 | −0.0731* | −0.1363 | |
| Medical aid | −0.0354 | −0.0791 | −0.1201 |
*Variables-related policies and times are significant (p<0.05).